DelveInsight’s, “Bronchopulmonary Dysplasia Pipeline Insight 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Research. Learn more about our innovative pipeline today! @ Bronchopulmonary Dysplasia Pipeline Outlook
Key Takeaways from the Bronchopulmonary Dysplasia Pipeline Report
- In September 2024:- EXO Biologics S.A.- Phase I Single Arm, Dose Escalating and Phase II Double Blind, Randomized, Placebo-controlled, Dose Finding Clinical Trial Assessing Safety and Efficacy of Intratracheal Administration of Allogeneic Umbilical Cord Mesenchymal Cells-derived Extracellular Vesicles in Preventing Bronchopulmonary Dysplasia in Extremely Preterm Newborns.
- DelveInsight’s Bronchopulmonary Dysplasia pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Bronchopulmonary Dysplasia treatment.
- The leading Bronchopulmonary Dysplasia Companies such as MEDIPOST Co., Ltd., Airway Therapeutics, Oak Hill Bio Ltd, Meridigen Biotech, AyuVis Research, CHIESI Farmaceutici S.p.A., Velvio, Orphanix, Alveolus Bio Inc., Advent Therapeutics, Trimunocor, The Cell Factory BVBA, Windtree Therapeutics, and others.
- Promising Bronchopulmonary Dysplasia Therapies such as Sildenafil, PNEUMOSTEM, OHB-607, and others.
Stay informed about the cutting-edge advancements in Bronchopulmonary Dysplasia Treatments. Download for updates and be a part of the revolution in cancer care @ Bronchopulmonary Dysplasia Clinical Trials Assessment
Bronchopulmonary Dysplasia Emerging Drugs Profile
- PNEUMOSTEM: MEDIPOST Co., Ltd.
PNEUMOSTEM® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is currently under development for the preventive treatment of Bronchopulmonary Dysplasia (BPD) in premature infants. Currently, Phase 2 clinical trial is ongoing in Korea and PNEUMOSTEM® has been Orphan Drug designated by US FDA and EMA. Recently, US FDA granted a Fast Track Designation for PNEUMOSTEM®.
- AT-100: Airway Therapeutics
AT-100 is a novel recombinant human protein rhSP-D, an engineered version of an endogenous protein that reduces inflammation and infection in the body while modulating the immune response to break the cycle of injury and inflammation. Airway is focused on advancing AT-100 for the prevention of BPD in very preterm born babies and as a therapeutic for seriously ill COVID-19 patients. AT-100’s anti-inflammatory and anti-infective properties also make it a potential treatment for other respiratory diseases such as influenza, respiratory syncytial virus (RSV) and inflammatory diseases outside the lung. The FDA and European Medicines Agency have granted AT-100 Orphan Drug Designation.
Learn more about Bronchopulmonary Dysplasia Drugs opportunities in our groundbreaking Inter Bronchopulmonary Dysplasia Research and development projects @ Bronchopulmonary Dysplasia Unmet Needs
Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Bronchopulmonary Dysplasia Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Discover the latest advancements in Bronchopulmonary Dysplasia Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Bronchopulmonary Dysplasia Market Drivers and Barriers, and Future Perspectives
Scope of the Bronchopulmonary Dysplasia Pipeline Report
- Coverage- Global
- Bronchopulmonary Dysplasia Companies- MEDIPOST Co., Ltd., Airway Therapeutics, Oak Hill Bio Ltd, Meridigen Biotech, AyuVis Research, CHIESI Farmaceutici S.p.A., Velvio, Orphanix, Alveolus Bio Inc., Advent Therapeutics, Trimunocor, The Cell Factory BVBA, Windtree Therapeutics, and others.
- Bronchopulmonary Dysplasia Therapies- Sildenafil, PNEUMOSTEM, OHB-607, and others.
- Bronchopulmonary Dysplasia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Bronchopulmonary Dysplasia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Bronchopulmonary Dysplasia Pipeline on our website @ Bronchopulmonary Dysplasia Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Bronchopulmonary Dysplasia: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Bronchopulmonary Dysplasia – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- PNEUMOSTEM: MEDIPOST Co., Ltd.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AT-100: Airway Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- AVR 48: AyuVis Research
- Drug profiles in the detailed report…..
- Inactive Products
- Bronchopulmonary Dysplasia Key Companies
- Bronchopulmonary Dysplasia Key Products
- Bronchopulmonary Dysplasia- Unmet Needs
- Bronchopulmonary Dysplasia- Market Drivers and Barriers
- Bronchopulmonary Dysplasia- Future Perspectives and Conclusion
- Bronchopulmonary Dysplasia Analyst Views
- Bronchopulmonary Dysplasia Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
